Skip to main content

Table 2 Corresponding IC50 values for each drug system at 24, 48 and 72 h incubation with cells

From: Fabrication of 6-gingerol, doxorubicin and alginate hydroxyapatite into a bio-compatible formulation: enhanced anti-proliferative effect on breast and liver cancer cells

Drug system

IC50 on MCF-7 cells (µg/mL)

IC50 on HEpG2 cells (µg/mL)

24 h

48 h

72 h

24 h

48 h

72 h

m-HAP

Inactive

Inactive

Inactive

Inactive

Inactive

Inactive

6-Gingerol

150.5 ± 10.6

102.4 ± 2.9

67.4 ± 6.9

118.9 ± 8.2

115.0 ± 7.9

32.1 ± 7.4

6-Gin-m-HAP

2.25 ± 0.73

1.38 ± 0.30

0.81 ± 0.17

44.9 ± 7.5

24.4 ± 7.8

3.43 ± 2.60

Doxorubicin

2.96 ± 0.96

3.03 ± 0.96

1.09 ± 0.46

53.0 ± 0.2

14.9 ± 4.1

1.14 ± 0.31

Dox-m-HAP

0.53 ± 0.15

0.43 ± 0.15

0.16 ± 0.05

7.69 ± 1.73

7.28 ± 2.19

0.58 ± 0.24

6-Gin + Dox-m-HAP

0.58 ± 0.07

0.53 ± 0.12

0.45 ± 0.09

0.55 ± 0.19

0.47 ± 0.05

0.19 ± 0.06

Back to article page

BMC Chemistry

ISSN: 2661-801X

Contact us